Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials

Guanghui Gao; Shengxiang Ren; Aiwu Li; Jianfang Xu; Qinghua Xu; Chunxia Su; Jian Guo; Qinfang Deng; Caicun Zhou

doi:10.1002/ijc.27396

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials

International Journal of Cancer ◽

10.1002/ijc.27396 ◽

2012 ◽

Vol 131 (5) ◽

pp. E822-E829 ◽

Cited By ~ 78

Author(s):

Guanghui Gao ◽

Shengxiang Ren ◽

Aiwu Li ◽

Jianfang Xu ◽

Qinghua Xu ◽

...

Keyword(s):

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Randomized Controlled ◽

Tyrosine Kinase Inhibitor Therapy ◽

Epidermal Growth

Download Full-text

Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study

Cancer ◽

10.1002/cncr.33385 ◽

2021 ◽

Author(s):

Keunchil Park ◽

Pasi A. Jӓnne ◽

Dong‐Wan Kim ◽

Ji‐Youn Han ◽

Ming‐Fang Wu ◽

...

Keyword(s):

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Tyrosine Kinase Inhibitor Therapy ◽

Phase 2 Study ◽

Epidermal Growth

Download Full-text

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2013.14.4.2413 ◽

2013 ◽

Vol 14 (4) ◽

pp. 2413-2419 ◽

Cited By ~ 17

Author(s):

S. Alimujiang ◽

Tao Zhang ◽

Zhi-Gang Han ◽

Shuai-Fei Yuan ◽

Qiang Wang ◽

...

Keyword(s):

Lung Cancer ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Controlled Trials ◽

Small Cell Lung ◽

Randomized Controlled ◽

Epidermal Growth

Download Full-text

Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis

Targeted Oncology ◽

10.1007/s11523-015-0373-x ◽

2015 ◽

Vol 11 (1) ◽

pp. 41-47 ◽

Cited By ~ 9

Author(s):

Gaetan Des Guetz ◽

Thierry Landre ◽

Bernard Uzzan ◽

Kader Chouahnia ◽

Patrick Nicolas ◽

...

Keyword(s):

Lung Cancer ◽

Receptor Tyrosine Kinase ◽

Survival Benefit ◽

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth

Download Full-text

Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non‐small‐cell lung cancer: Systematic review and meta analysis

Thoracic Cancer ◽

10.1111/1759-7714.12343 ◽

2016 ◽

Vol 7 (4) ◽

pp. 406-414 ◽

Cited By ~ 12

Author(s):

Yinghui Liu ◽

Zuen Ren ◽

Jinghui Wang ◽

Shucai Zhang

Keyword(s):

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Tyrosine Kinase Inhibitor Therapy ◽

Exon 19 Deletion ◽

Epidermal Growth ◽

L858r Mutation

Download Full-text

Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis

Thoracic Cancer ◽

10.1111/j.1759-7714.2011.00051.x ◽

2011 ◽

Vol 2 (3) ◽

pp. 101-108

Author(s):

Xiao-Hang Zhang ◽

Cheng Li ◽

Chen-Fei Dai ◽

Bao-Sen Zhou

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell Lung ◽

Tyrosine Kinase Inhibitor Therapy ◽

Epidermal Growth

Download Full-text

A meta-analysis of smoking status on clinical outcomes of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8101 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8101-8101

Author(s):

Yoshikazu Hasegawa ◽

Masahiko Ando ◽

Makoto Maemondo ◽

Satomi Yamamoto ◽

Shun-ichi Isa ◽

...

Keyword(s):

Kinase Inhibitor ◽

Smoking Status ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Egfr Mutations ◽

Small Cell Lung ◽

First Line ◽

Egfr Tyrosine Kinase Inhibitor ◽

Lung Cancer Patients ◽

Epidermal Growth

Download Full-text

Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non–Small-Cell Lung Cancer andEGFRMutations?

Journal of Clinical Oncology ◽

10.1200/jco.2013.52.8794 ◽

2014 ◽

Vol 32 (8) ◽

pp. 859-863 ◽

Cited By ~ 2

Author(s):

Eva R. Haspinger ◽

Marina Chiara Garassino ◽

Valter Torri ◽

Michela Cinquini ◽

Filippo De Braud ◽

...

Keyword(s):

Lung Cancer ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials

Current Medical Research and Opinion ◽

10.1185/03007995.2014.978448 ◽

2014 ◽

Vol 31 (1) ◽

pp. 25-33 ◽

Cited By ~ 4

Author(s):

Wei-Xiang Qi ◽

Shen Fu ◽

Qing Zhang ◽

Xiao-Mao Guo

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase Iii ◽

Controlled Trials ◽

Small Cell Lung ◽

Randomized Controlled ◽

Epidermal Growth

Download Full-text

Abstract B072: Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with disease control after first-line chemotherapy or during therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: Updated clinical results and immune responses

10.1158/2326-6066.imm2016-b072 ◽

2016 ◽

Cited By ~ 1

Author(s):

M. M. Hipp ◽

M. Sebastian ◽

C. Weiss ◽

M. Früh ◽

M. Pless ◽

...

Keyword(s):

Immune Responses ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Stage Iv ◽

Clinical Results ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Line Chemotherapy

Download Full-text

Interstitial Lung Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Carcinoma

Clinical Lung Cancer ◽

10.3816/clc.2006.s.011 ◽

2006 ◽

Vol 8 ◽

pp. S31-S35 ◽

Cited By ~ 15

Author(s):

Ken Y. Yoneda ◽

Kimberly A. Hardin ◽

David R. Gandara ◽

David K. Shelton

Keyword(s):

Epidermal Growth Factor Receptor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Small Cell Lung Carcinoma ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Tyrosine Kinase Inhibitor Therapy ◽

Epidermal Growth

Download Full-text